Gilead to acquire oral IL-23R inhibitor for $1.28 billion
In
Investing.comBy Investing.com10/22/2026, 8:12:37 PM
EXECUTIVE SUMMARY
Gilead to acquire oral IL-23R inhibitor for $1.28 billion....
Key Takeaways
- Gilead to acquire oral IL-23R inhibitor for $1.28 billion.
Read Complete Original Article
Published originally on Investing.com
Related News
finance20 minutes ago
SpaceX says Tesla merger would need Musk’s approval
SpaceX says Tesla merger would need Musk’s approval....
finance21 minutes ago
Western Digital shares slide as cost pressures, higher capex overshadow earnings
Western Digital shares slide as cost pressures, higher capex overshadow earnings....
finance22 minutes ago
RBC Capital reiterates Merck stock rating on melanoma trial data
RBC Capital reiterates Merck stock rating on melanoma trial data....
finance23 minutes ago
Quaker Chemical appoints Neil Daniels as chief accounting officer
Quaker Chemical appoints Neil Daniels as chief accounting officer....
Multikhabar App
All Information In One Place
Real-time headlines from trusted sources. Get the app now — stay updated, inspired, and ahead with breaking news!